Astrazeneca PLC Sponsored ADR (AZN.US) breast cancer class 1 innovative drug approved in China

On April 18, the latest announcement on the official website of the National Medical Products Administration (NMPA) of China revealed the approval of Astrazeneca PLC Sponsored ADR (AZN.US) Class 1 innovative drug Capivasertib tablets for marketing. The product was approved for marketing by the US FDA in November 2023 (brand name: Truqap), for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer in adult patients. Screenshot source: NMPA official website Public information indicates that this is a "first-in-class" AKT inhibitor. The drug is indicated for use in combination with fulvestrant in patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer who have progressed after at least one prior endocrine therapy in the metastatic setting, or within 12 months of adjuvant treatment completion or during adjuvant treatment and have a PIK3CA/AKT1/PTEN alteration.